Management of psychosis in Parkinson's disease

Current Opinion in Neurology

Volumn 14, Issue 4, 2001, Pages 499-504

  Wolters, Erik Ch ^a   Berendse, Henk W ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; SEROTONIN RECEPTOR;

DELIRIUM; DELUSION; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSENSITIVITY; LEWY BODY; NEUROLEPTIC MALIGNANT SYNDROME; NURSING HOME; PARKINSON DISEASE; PARKINSONISM; PSYCHOSIS; REVIEW; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; PARKINSON DISEASE; PROGNOSIS;

EID: 0034901147     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-200108000-00011     Document Type: Review

References (43)

1. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors
2. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: A community-based study
3. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease
4. Rivastagmine in the treatment of dementia with Lewy bodies: Preliminary findings from an open trial
5. Genetic variation analysis in Parkinson disease patients with and without hallucinations: Case-control study
6. Apolipoprotein E e4 increases the risk of drug-induced hallucinations in Parkinson's disease
7. Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis
8. Psychosis: Impact on the patient and family
9. Visual hallucinations in Parkinson and Charles Bonnet syndrome patients. A phenomenological and pathogenetic comparison
10. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study
11. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
12. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies
13. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: Role of 5-HT2 receptor and alpha-1 adrenoceptor antagonism
14. Morphological substrates of mental dysfunction in Lewy body disease: An update
15. Managing psychosis in patients with Parkinson's disease
16. Management of behavioral and psychiatric problems in Parkinson's disease
17. Dopaminomimetic psychosis in Parkinson's disease patients: Diagnosis and treatment
18. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors
19. Behavioural problems associated with dementia: The role of newer antipsychotics
20. Psychosis in lewy body parkinsonism
21. Clozapine in drug-induced psychosis in Parkinson's disease
22. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
23. Management of psychotic aspects of Parkinson's disease
24. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease
25. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease
26. Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
27. Efficacy of quetiapine in Parkinson's patients with psychosis
28. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease
29. Quetiapine for L-dopa-induced psychosis in PD
30. Quetiapine for L-dopa-induced psychosis in PD
31. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease
32. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia
33. Worsening of motor features of parkinsonism with olanzapine
34. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine
35. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
36. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
37. Risperidone treatment of drug-related psychosis in patients with parkinsonism
38. Clozapine and risperidone treatment of psychosis in Parkinson's disease
39. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
40. Comparison of risperidone and placebo for psychosis and behavioural disturbances associated with dementia: A randomized, double-blind trial
41. Neurologic side effects in neuroleptic-naive patients treated with haloperidol or risperidone
42. Improvement in sundowning in dementia with Lewy bodies after treatment with donezepil